Saturday 17 October 2026
Export GNPX’s income statement to Excel — free account
GENPREX
GNPX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.0% and free cash flow fell 33.0%, each against the same quarter a year earlier.
2.11
0.18
−7.86%
Follow GNPX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
3.84 | 0.83 | 2.31 | 7.64 | 24.69 | 61.47 | 5.83 | 22.81 | 0.23 | 5.74 |
Net Debt/EBITDA |
0.50 | 0.08 | 0.22 | 0.88 | 1.87 | 1.52 | 0.19 | 0.70 | 0.05 | 0.39 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.94 | 0.84 | 0.80 | 0.74 | 0.69 | 0.78 | 0.65 | 0.55 | 0.66 | 0.30 |
Capex/Depreciation |
— | 115.63 | (4.75) | (2.33) | (3.22) | (5.61) | (11.08) | (17.51) | (19.81) | (99.56) |
Interest Coverage |
— | — | — | (264.49) | (4,052.96) | (955.40) | (382.89) | (325.36) | (1,743.32) | — |
| (338.74%) | (473.37%) | (207.88%) | (74.71%) | (57.25%) | (105.73%) | (179.00%) | (265.79%) | (322.79%) | (402.45%) | |
| (227.24%) | (289.13%) | (172.62%) | (69.88%) | (55.68%) | (102.82%) | (166.44%) | (235.02%) | (209.10%) | (260.71%) | |
ROIC |
(7,402.48%) | (71,534.46%) | (2,859.54%) | (1,127.83%) | (487.85%) | (312.11%) | (653.94%) | (2,757.74%) | (774.48%) | (11,427.54%) |
Return on Tangible Assets |
(262.51%) | 5,012.49% | (720.11%) | (127.05%) | (54.95%) | (65.74%) | (424.39%) | (145.84%) | 526.40% | (304.22%) |
Average Days of Receivables |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.07 | 0.03 | 0.02 | 0.02 | 0.14 | 0.04 | 0.24 | 0.13 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(360.26) | (4,763.31) | (20,674.83) | (16,073.82) | (13,052.09) | (17,578.87) | (17,659.50) | (23,166.00) | (7,450.00) | (6,689.50) |
Cash per Share |
184.26 | 444.92 | 5,614.67 | 19,049.18 | 35,117.18 | 34,149.63 | 5,006.25 | 28,669.67 | 537.67 | 8,011.50 |
Shareholders Equity per Share |
187.34 | 450.06 | 6,180.33 | 20,249.73 | 37,524.55 | 38,645.63 | 7,558.75 | 29,603.67 | 1,428.67 | 8,124.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
187.34 | 450.06 | 6,180.33 | 20,249.73 | 37,524.55 | 38,645.63 | 7,558.75 | 29,603.67 | 1,428.67 | 8,124.50 |
Free Cash Flow |
(15.31) | (17.15) | (24.81) | (17.68) | (14.36) | (14.06) | (7.06) | (6.95) | (2.23) | (1.34) |
Working Capital |
6.18 | (0.43) | 4.28 | 18.66 | 37.55 | 27.25 | 2.47 | 8.46 | (0.64) | 1.35 |
Capital Expenditures |
— | 0.77 | (0.07) | (0.06) | (0.07) | (0.13) | (0.15) | (0.10) | (0.06) | (0.09) |
Net Current Asset Value |
6.16 | (0.43) | 4.28 | 18.66 | 37.55 | 27.25 | 2.47 | 8.46 | (0.64) | 1.35 |
| Other line items | ||||||||||
Quick Ratio |
3.60 | 0.64 | 2.07 | 7.47 | 24.37 | 60.62 | 3.92 | 22.20 | 0.20 | 5.64 |
Depreciation/Fixed assets |
— | 0.00 | 1.90 | 1.11 | 0.46 | 0.58 | 0.29 | 0.24 | 0.41 | 0.17 |
Cash ROIC |
(96.95%) | (532.23%) | (175.28%) | (40.90%) | (17.97%) | (24.15%) | (140.55%) | (39.75%) | (378.88%) | (41.46%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(360.26) | (4,978.50) | (20,615.50) | (16,019.55) | (12,986.27) | (17,418.87) | (17,296.75) | (22,821.67) | (7,238.67) | (6,241.50) |
Capex per Share |
0.00 | 215.19 | (59.33) | (54.27) | (65.82) | (160.00) | (362.75) | (344.33) | (211.33) | (448.00) |
Average Receivables |
— | — | — | 0.02 | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
Average Payables |
0.91 | 1.24 | 0.92 | 0.71 | 0.58 | 0.31 | 0.37 | 0.46 | 0.46 | 0.46 |
Average Inventory |
— | — | — | — | — | 1.91 | 1.91 | — | — | — |
Average Assets |
7.14 | 7.40 | 17.88 | 33.97 | 37.11 | 17.45 | 6.40 | 5.26 | 1.59 | 1.59 |
Average Common Equity |
4.79 | 4.52 | 14.85 | 31.78 | 36.10 | 16.97 | 5.95 | 4.65 | 1.03 | 1.03 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates